Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice

Ähnliche Einträge

• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  von: Faisal I. Almohaileb, et al.
  Veröffentlicht: (2025)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  von: Yunwen Xu, et al.
  Veröffentlicht: (2025)
• Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
  von: Mona Abdel‐Bary, et al.
  Veröffentlicht: (2025)
• Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
  von: Yu‐Nan Huang, et al.
  Veröffentlicht: (2024)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  von: David C. Klonoff, et al.
  Veröffentlicht: (2024)